Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Xevinapant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients
    Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients

    07 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220907005443/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    Xevinapant Show Survival Rate Nearly Doubled in with Unresected LA SCCHN
    Xevinapant Show Survival Rate Nearly Doubled in with Unresected LA SCCHN

    07 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220907005018/en

    BUSINESSWIRE
    07 Sep 2022
    Share Share
    Debiopharm Launches TrilynX - A Large-Scale Ph III Trial to Xevinapant
    Debiopharm Launches TrilynX - A Large-Scale Ph III Trial to Xevinapant

    01 Oct 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/debiopharm-launches-trilynx---a-large-scale-phase-iii-clinical-trial-to-further-evaluate-xevinapant-in-the-treatment-of-head--neck-cancer-301143930.html

    PRNEWSWIRE
    01 Oct 2020
    Share Share